1. At a Glance – From Zero to ₹139 Cr TTM… and Promoters Almost Zero Too?
Market Cap: ₹329 Cr
Current Price: ₹78
Stock P/E: 33.7
Book Value: ₹40.5
ROE: 30.1%
ROCE: 34.8%
Debt: ₹12.7 Cr
3-Month Return: -12.7%
Astal Laboratories is that one guy from school who disappeared after 10th standard and suddenly came back with a startup pitch and LinkedIn profile saying “Serial Entrepreneur.” For years, the company did almost nothing. Zero revenue. Zero excitement. Zero dividend.
Then boom. TTM sales: ₹139 Cr. Profit after tax: ₹9.77 Cr. Q3 FY26 revenue alone: ₹52.24 Cr — up 261% YoY.
But wait… promoter holding? 4.64%.
Yes, you read that right. The promoters have almost left the building.
The stock trades at 33.7 times earnings, slightly above industry median of 28.5. It boasts a 30% ROE, 34.8% ROCE, and a PEG ratio of 0.05 (which looks suspiciously attractive).
Is this a turnaround story?
A backdoor pharma transformation?
Or a corporate makeover with dramatic share dilution?
Let’s investigate.
2. Introduction – From Saddles to Pharma Deals
Astal Laboratories wasn’t always a “laboratory.”
Originally incorporated in 1993 as Macro International Ltd, the company used to export saddlery products — bridles, halters, leather straps — basically, if a horse needed it, they sold it. They also ran a departmental store in Kanpur.
Then business shut down.
For years, there was practically no operational activity. In FY21, the company didn’t generate any revenue from operations. Only “Other Income” like interest and tax refunds kept it alive. That’s like surviving on cashback offers.
Then things changed.
From FY23 onwards, revenue started appearing. By FY24, sales were ₹24 Cr. By FY25, ₹64 Cr. Now TTM? ₹139 Cr.
That’s not gradual growth. That’s resurrection.
But here’s the twist — multiple preferential allotments, share swaps, and acquisitions happened in 2025 and early 2026. The company acquired 100% of Sriven Pharmachem via share swap worth ₹277.17 Cr.
So effectively, Astal transformed from a dormant shell into a pharmaceutical play via acquisition.
But when you issue 3+ crore shares for acquisitions, something else happens. Ownership changes.
Promoter holding fell from 61% in mid-2023… to 4.64% by January 2026.
Let that sink in.
Would you trust a company where original promoters almost exited?
3. Business Model – WTF Do They Even Do?
Let’s simplify this.
Old Astal:
Sold horse accessories and ran a departmental store.
New Astal:
Acquired pharmaceutical manufacturing assets.
In October 2025, the board approved acquisition of 100% of Sriven Pharmachem via a 1:1 share swap. Consideration: ₹277.17 Cr.
Additional announcements include:
- Acquisition of pharmaceutical intermediates plant (Oct 2024)
- LOI with Immuna Therapeutics for CAR-T rights in India (Dec 2025) — estimated incremental ₹300 Cr revenue
- Swiss LOI for 60 tonnes of Piroctone Olamine (Nov 2025)
- REACH certification
